Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions.Development Agreement • November 14th, 2014 • Argos Therapeutics Inc • Pharmaceutical preparations • England and Wales
Details 4 Agreed terms 5 1. Defined terms & interpretation 5 2. Development of the Production System 11 3. Prototypes and acceptance procedures 15 4. Terms of Payment 16 5. Deferred Fees 17 6. GST 20 7. Replication Arrangement 21 8. Intellectual property rights 21 9. Confidential Information 25 10. Inspection of Records 27 11. Reliance on information, results, Products, etc 27 12. Compliance and regulatory 27 13. Representations and warranties 28 14. Exclusion of warranties and limited liability 29 15. Indemnity 31 16. Insurance 32 17. Term and termination 32 18. Dispute resolution 35 19. Good faith and Non-Solicitation 36 20. Notices and other communications 36 21. Miscellaneous 36 Schedule 1 – Key Details 39 Schedule 2 – Program Milestones 40 Schedule 3 – Generic Program IP 41 Schedule 4 – Invetech Key Personnel 43 Schedule 5 – Specialist Program IP 44
